Defecation FrequencyNCT06911177
Yeast Mannans and Stool Frequency
A study testing Yeast mannan in people with Defecation Frequency, run by University of Florida at 1 site in United States.
Trial summary
Findings from an open-label pilot study of 20 adults suggested that supplementation with 15 g/day of yeast mannans was highly tolerable and demonstrated specific modulation of the microbiota and increased stool frequency in a subset of subjects reporting ≤1 stool per day at baseline. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Defecation Frequency
- What is being tested?
- Yeast mannan
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Jul 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults who report a stool frequency of ≤ 1 per day.
- Able to provide written informed consent in English.
- Willingness to consume 1 supplement (12 g of yeast mannans or control) daily for 28 days.
- Willingness to maintain their usual diet and physical activity patterns throughout the study and refrain from the consumption of any yeast-based foods (e.g. Marmite or Vegemite) or yeast extract supplements.
- Willing to comply with study procedures, including stool and urine colle
Who cannot join
- Stool frequency of < 3 per week
- Yeast allergy
- Vegan dietary pattern
- Self-reported kidney disease
- Elite athletes or long-distance runners
- Use of antibiotic drugs within 1 month of screening
Show all 12Show fewer
- Current use of laxatives or antidiarrheal medications
- Use of other investigational products within 3 months of the screening
- Previously or currently being treated for intestinal diseases or conditions, including irritable bowel disease (i.e., IBS-D or IBS-mixed), Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer.
- Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection).
- Current cancer treatment.
- Currently pregnant.
Trial locations and contacts
1 site in 1 country.
United States1 site
Department of Food Science and Human Nutrition
Gainesville, Florida, 32611
About this study
Official title: Efficacy of Yeast Mannan Supplementation on Increasing Stool Frequency in Generally Healthy Adults: A Randomized Controlled Trial
Findings from an open-label pilot study of 20 adults suggested that supplementation with 15 g/day of yeast mannans was highly tolerable and demonstrated specific modulation of the microbiota and increased stool frequency in a subset of subjects reporting ≤1 stool per day at baseline. The primary aim of this randomized, double-blind, controlled trial is to determine if yeast mannan supplementation at 12 g/day will increase stool frequency in generally healthy adults reporting ≤1 stool per day. Secondary aims will determine the effect of yeast mannans on intestinal transit time, gastrointestinal symptoms, fecal microbiota composition, and urinary and fecal metabolomics.
- Conditions
- Defecation Frequency
- Being tested
- Yeast mannan, Control (placebo)
- Keywords
- yeast mannan, stool frequency, transit time, microbiota
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Yeast mannanDietary supplement
Also called yeast cell wall fraction
Yeast cell wall fraction of manno-oligosaccharides and mannoproteins supplemented at 12 g/day.
Control (placebo)Dietary supplement
A supplement containing yeast protein, yeast extract, and maltodextrin, provided at 12 g/day.
| Study group | Role | What they receive |
|---|---|---|
| Yeast mannan supplementation | Experimental | Yeast cell wall fraction obtained from Saccharomyces cerevisiae containing mannan-oligosaccharides and mannoproteins will be supplemented at 12 g/day. Receives: Dietary Supplement: Yeast mannan |
| Control supplementation | Placebo comparator | The control supplement, containing yeast protein, yeast extract, and maltodextrin, will be provided at 12 g/day. Receives: Dietary Supplement: Control (placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Defecation frequency
Mean daily defecation frequency
Measured: From enrollment to the end of treatment at 6 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2025
- Study start17 Jul 2025
- Primary completion16 Mar 2026
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Defecation FrequencyStudies of the same condition, open and under way.
- More trials run by University of FloridaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06911177
- Sponsor's protocol ID
- IRB202500359
- Status last verified
- Aug 2025
- First submitted
- 28 Mar 2025
- Last updated
- 15 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Moreno ML, Taft DH, Tompkins TA, Dahl WJ. Efficacy of yeast mannan supplementation on increasing stool frequency in adults: a randomized controlled trial. Trials. 2026 Jul 28;27(1):623. doi: 10.1186/s13063-026-09921-y.
PubMed 42919413
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Yeast Mannan Supplementation on Increasing Stool Frequency in Generally Healthy Adults: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06911177
- Acronym / sponsor ID
- IRB202500359
- Conditions
- Defecation Frequency
- Keywords
- yeast mannan, stool frequency, transit time, microbiota
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- University of FloridaUniversity, hospital or other
- Study start
- 17 Jul 2025 (actual)
- Primary completion
- 16 Mar 2026 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 4 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Findings from an open-label pilot study of 20 adults suggested that supplementation with 15 g/day of yeast mannans was highly tolerable and demonstrated specific modulation of the microbiota and increased stool frequency in a subset of subjects reporting ≤1 stool per day at baseline. The primary aim of this randomized, double-blind, controlled trial is to determine if yeast mannan supplementation at 12 g/day will increase stool frequency in generally healthy adults reporting ≤1 stool per day. Secondary aims will determine the effect of yeast mannans on intestinal transit time, gastrointestinal symptoms, fecal microbiota composition, and urinary and fecal metabolomics.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Yeast mannan supplementation | Experimental | Dietary Supplement: Yeast mannanYeast cell wall fraction obtained from Saccharomyces cerevisiae containing mannan-oligosaccharides and mannoproteins will be supplemented at 12 g/day. |
| Control supplementation | Placebo comparator | Dietary Supplement: Control (placebo)The control supplement, containing yeast protein, yeast extract, and maltodextrin, will be provided at 12 g/day. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults who report a stool frequency of ≤ 1 per day.
- Able to provide written informed consent in English.
- Willingness to consume 1 supplement (12 g of yeast mannans or control) daily for 28 days.
- Willingness to maintain their usual diet and physical activity patterns throughout the study and refrain from the consumption of any yeast-based foods (e.g. Marmite or Vegemite) or yeast extract supplements.
- Willing to comply with study procedures, including stool and urine colle
Key exclusion criteria (12 listed)
- Stool frequency of < 3 per week
- Yeast allergy
- Vegan dietary pattern
- Self-reported kidney disease
- Elite athletes or long-distance runners
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Yeast mannanAlso: yeast cell wall fractionYeast cell wall fraction of manno-oligosaccharides and mannoproteins supplemented at 12 g/day. | Dietary supplement | Yeast mannan supplementation |
| Control (placebo)A supplement containing yeast protein, yeast extract, and maltodextrin, provided at 12 g/day. | Dietary supplement | Control supplementation |
Primary outcome
Defecation frequency
Time frame: From enrollment to the end of treatment at 6 weeks.
Mean daily defecation frequency
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
- Derived from this study: PubMed 42919413Moreno ML, Taft DH, Tompkins TA, Dahl WJ. Efficacy of yeast mannan supplementation on increasing stool frequency in adults: a randomized controlled trial. Trials. 2026 Jul 28;27(1):623. doi: 10.1186/s13063-026-09921-y.
- Individual participant dataSharing planned: Undecided
Related trials for Defecation Frequency
RecruitingPhase 1/2
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
Ileal Pouch
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Yeast mannan in people with Defecation Frequency, run by University of Florida at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Defecation frequency (time frame: From enrollment to the end of treatment at 6 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06911177, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.